- Home
- FYBR vs ASND Comparison
FYBR vs ASND Comparison
Compare FYBR & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- ASND
- Stock Information
- Founded
- FYBR 1935
- ASND 2006
- Country
- FYBR United States
- ASND Denmark
- Employees
- FYBR N/A
- ASND N/A
- Industry
- FYBR Telecommunications Equipment
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- FYBR Consumer Discretionary
- ASND Health Care
- Exchange
- FYBR Nasdaq
- ASND Nasdaq
- Market Cap
- FYBR 9.0B
- ASND 9.1B
- IPO Year
- FYBR N/A
- ASND 2015
- Fundamental
- Price
- FYBR $36.11
- ASND $165.05
- Analyst Decision
- FYBR Buy
- ASND Strong Buy
- Analyst Count
- FYBR 10
- ASND 15
- Target Price
- FYBR $34.57
- ASND $202.00
- AVG Volume (30 Days)
- FYBR 3.4M
- ASND 506.0K
- Earning Date
- FYBR 04-29-2025
- ASND 05-01-2025
- Dividend Yield
- FYBR N/A
- ASND N/A
- EPS Growth
- FYBR N/A
- ASND N/A
- EPS
- FYBR N/A
- ASND N/A
- Revenue
- FYBR $5,937,000,000.00
- ASND $376,478,932.00
- Revenue This Year
- FYBR $4.41
- ASND $61.43
- Revenue Next Year
- FYBR $2.92
- ASND $73.07
- P/E Ratio
- FYBR N/A
- ASND N/A
- Revenue Growth
- FYBR 3.23
- ASND 36.34
- 52 Week Low
- FYBR $21.31
- ASND $111.09
- 52 Week High
- FYBR $39.21
- ASND $169.37
- Technical
- Relative Strength Index (RSI)
- FYBR 60.74
- ASND 62.95
- Support Level
- FYBR $35.44
- ASND $152.07
- Resistance Level
- FYBR $36.20
- ASND $159.14
- Average True Range (ATR)
- FYBR 0.28
- ASND 10.95
- MACD
- FYBR 0.03
- ASND 1.28
- Stochastic Oscillator
- FYBR 89.83
- ASND 99.11
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.